c-Fms Signaling Mediates Neurofibromatosis Type-1 Osteoclast Gain-In-Functions

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  He, Yongzheng ^a   Rhodes, Steven D ^a   Chen, Shi ^a   Wu, Xiaohua ^a   Yuan, Jin ^a   Yang, Xianlin ^a   Jiang, Li ^a   Li, Xianqi ^b   Takahashi, Naoyuki ^b   Xu, Mingjiang ^a   Mohammad, Khalid S ^a   Guise, Theresa A ^a   Yang, Feng Chun ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MATSUMOTO DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN C FMS; PROTEIN P90; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MASS; BONE STRUCTURE; CELL ACTIVATION; CELL ADHESION; CELL DIFFERENTIATION; CELL FUNCTION; CELL MIGRATION; CONTROLLED STUDY; HAPLOINSUFFICIENCY; IN VIVO STUDY; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; OVARIECTOMY; SIGNAL TRANSDUCTION; STEM CELL;

ANIMALS; BONE RESORPTION; CELL ADHESION; CELL MOVEMENT; CELLS, CULTURED; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE DELETION; HUMANS; MACROPHAGE COLONY-STIMULATING FACTOR; MICE; MICE, INBRED C57BL; NEUROFIBROMIN 1; OSTEOCLASTS; OSTEOPOROSIS; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SIGNAL TRANSDUCTION;

MUS;

EID: 84868705440     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046900     Document Type: Article

References (40)

1. Lammert M, Friedman JM, Kluwe L, Mautner VF, (2005) Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol 141: 71-74.
2. Hiatt KK, Ingram DA, Zhang Y, Bollag G, Clapp DW, (2001) Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1-/- cells. J Biol Chem 276: 7240-7245.
3. Riccardi VM, (1981) Von Recklinghausen neurofibromatosis. N Engl J Med 305: 1617-1627.
4. Friedman JM (2002) Neurofibromatosis 1: clinical manifestations and diagnostic criteria. J Child Neurol 17: 548-554; discussion 571-542, 646-551.
5. Kuorilehto T, Poyhonen M, Bloigu R, Heikkinen J, Vaananen K, et al. (2005) Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body. Osteoporos Int 16: 928-936.
6. Lammert M, Kappler M, Mautner VF, Lammert K, Storkel S, et al. (2005) Decreased bone mineral density in patients with neurofibromatosis 1. Osteoporos Int 16: 1161-1166.
7. Illes T, Halmai V, de Jonge T, Dubousset J, (2001) Decreased bone mineral density in neurofibromatosis-1 patients with spinal deformities. Osteoporos Int 12: 823-827.
8. Jacques C, Dietemann JL, (2005) [Imaging features of neurofibromatosis type 1]. J Neuroradiol 32: 180-197.
9. Stevenson DA, Zhou H, Ashrafi S, Messiaen LM, Carey JC, et al. (2006) Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum Genet 79: 143-148.
10. Brunetti-Pierri N, Doty SB, Hicks J, Phan K, Mendoza-Londono R, et al. (2008) Generalized metabolic bone disease in Neurofibromatosis type I. Mol Genet Metab. 94: 105-111.
11. Seitz S, Schnabel C, Busse B, Schmidt HU, Beil FT, et al. (2010) High bone turnover and accumulation of osteoid in patients with neurofibromatosis 1. Osteoporos Int 21: 119-127.
12. Stevenson DA, Moyer-Mileur LJ, Murray M, Slater H, Sheng X, et al. (2007) Bone mineral density in children and adolescents with neurofibromatosis type 1. J Pediatr 150: 83-88.
13. Heerva E, Koffert A, Jokinen E, Kuorilehto T, Peltonen S, et al. (2012) A controlled register based study of 460 neurofibromatosis 1 (NF1) patients: Increased fracture risk in children and adults over 41 years. J Bone Miner Res.
14. Crawford AH Jr, Bagamery N, (1986) Osseous manifestations of neurofibromatosis in childhood. J Pediatr Orthop 6: 72-88.
15. Friedman JM, Birch PH, (1997) Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients. Am J Med Genet 70: 138-143.
16. Elefteriou F, Kolanczyk M, Schindeler A, Viskochil DH, Hock JM, et al. (2009) Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options. Am J Med Genet A 149A: 2327-2338.
17. Mondal R, Nandi M, Chandra PK Neurofibromatosis, pathological fracture and hypervitaminosis-D. Indian Pediatr 47: 881-882.
18. Yang FC, Chen S, Robling AG, Yu X, Nebesio TD, et al. (2006) Hyperactivation of p21ras and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J Clin Invest 116: 2880-2891.
19. Yan J, Chen S, Zhang Y, Li X, Li Y, et al. (2008) Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1. Hum Mol Genet 17: 936-948.
20. Heerva E, Alanne MH, Peltonen S, Kuorilehto T, Hentunen T, et al. (2010) Osteoclasts in neurofibromatosis type 1 display enhanced resorption capacity, aberrant morphology, and resistance to serum deprivation. Bone 47: 583-590.
21. Alanne MH, Siljamaki E, Peltonen S, Vaananen K, Windle JJ, et al. (2012) Phenotypic characterization of transgenic mice harboring Nf1(+/-) or Nf1(-/-) osteoclasts in otherwise Nf1(+/+) background. J Cell Biochem.
22. He Y, Staser K, Rhodes SD, Liu Y, Wu X, et al. (2011) Erk1 positively regulates osteoclast differentiation and bone resorptive activity. PLoS One 6: e24780.
23. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, et al. (1994) Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 7: 353-361.
24. Wu X, Chen S, He Y, Rhodes SD, Mohammad KS, et al. (2011) The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1. PLoS One 6: e24917.
25. Zhang W, Rhodes SD, Zhao L, He Y, Zhang Y, et al. (2011) Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model. Bone 48: 1378-1387.
26. Yilmaz K, Ozmen M, Bora Goksan S, Eskiyurt N, (2007) Bone mineral density in children with neurofibromatosis 1. Acta Paediatr 96: 1220-1222.
27. Dulai S, Briody J, Schindeler A, North KN, Cowell CT, et al. (2007) Decreased bone mineral density in neurofibromatosis type 1: results from a pediatric cohort. J Pediatr Orthop 27: 472-475.
28. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, et al. (1990) The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345: 442-444.
29. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176.
30. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, et al. (1998) Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95: 3597-3602.
31. Raisz LG, (2005) Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 115: 3318-3325.
32. Golden LH, Insogna KL, (2004) The expanding role of PI3-kinase in bone. Bone 34: 3-12.
33. Pilkington MF, Sims SM, Dixon SJ, (1998) Wortmannin inhibits spreading and chemotaxis of rat osteoclasts in vitro. J Bone Miner Res 13: 688-694.
34. Palacio S, Felix R, (2001) The role of phosphoinositide 3-kinase in spreading osteoclasts induced by colony-stimulating factor-1. Eur J Endocrinol 144: 431-440.
35. Nakamura I, Takahashi N, Sasaki T, Tanaka S, Udagawa N, et al. (1995) Wortmannin, a specific inhibitor of phosphatidylinositol-3 kinase, blocks osteoclastic bone resorption. FEBS Lett 361: 79-84.
36. Anthony SP, Puzanov I, Lin PS, Nolop KB, West B, et al. (2011) Pharmacodynamic activity demonstrated in phase I for PLX3397, a selective inhibitor of FMS and Kit. J Clin Oncol (suppl; abstr 3093) 29.
37. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffekk B, Shiao SL, et al. (2011) Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Drug Discovery 1: 54-67.
38. Liggett W Jr, Shevde N, Anklesaria P, Sohoni S, Greenberger J, et al. (1993) Effects of macrophage colony stimulating factor and granulocyte-macrophage colony stimulating factor on osteoclastic differentiation of hematopoietic progenitor cells. Stem Cells 11: 398-411.
39. Biskobing DM, Fan X, Rubin J, (1995) Characterization of MCSF-induced proliferation and subsequent osteoclast formation in murine marrow culture. J Bone Miner Res 10: 1025-1032.
40. Otero K, Turnbull IR, Poliani PL, Vermi W, Cerutti E, et al. (2009) Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and beta-catenin. Nat Immunol 10: 734-743.